Cryonics Questions and Choices
A hard question sits at the center of cryonics: how can a body be cooled without turning its cells into wreckage? That is the real science problem, and it is the one that shapes every step from standby to preservation.
Cryonics begins after legal death. It is not a treatment for a living person. From that point on, the work is about slowing damage as fast as possible.
The first challenge is ice. When water freezes, it does not freeze evenly. Pure ice forms first, and the remaining liquid becomes saltier. That can dehydrate cells and damage them in two ways. Ice crystals can break structure, and the leftover fluid can become harsh enough to injure tissue.
That is why cryonics uses cryoprotectants. These are water-soluble chemicals that lower the freezing point of water and help limit ice formation. A useful concentration is often in the range of 5 to 15 percent, though the exact level depends on the tissue and the method.
Early work used DMSO, but later practice found glycerol to be a better protector in many protocols. Today, the field uses a small group of compounds rather than the many that have been studied. Some cryoprotectants are penetrating. They are small enough to cross cell membranes. Others are non-penetrating. These are larger polymers that stay outside cells and help block ice growth in the spaces around them.
The liquid that carries these agents matters too. It is called the carrier solution or base perfusate. It is kept near normal body fluid strength, about 300 mOsm/kg, so cells do not shrink or swell too violently during loading. That balance sounds small. It is not. Cells react quickly when the fluid around them changes.
For whole organs, the chemicals cannot be added all at once. The usual method is multi-step perfusion. The concentration rises in stages, often through quarter, half, and full strength steps, with time at each step near 0°C. This slower loading helps the tissue adapt and limits shock. It also matters because the blood-brain barrier does not let large penetrating molecules pass freely. In the brain, concentration changes must be managed with care.
A simple example makes this easier to picture. Imagine a sponge that is being replaced with a new liquid. If the new liquid arrives too fast, the sponge twists and tears. If it arrives in steps, the change is gentler. Cryonics tries to make tissue behave more like the second case.
There is another path called vitrification. Instead of letting water form ice, the tissue is loaded with enough cryoprotectant that the whole volume can turn into a glass-like solid as it cools. Below about -100°C, the remaining unfrozen liquid becomes glass. That can reduce the mechanical damage caused by ice. But vitrification asks for higher protection and careful temperature control. Cooling and warming must be handled with discipline, because cryoprotectant toxicity rises near 0°C even when the same chemical behaves differently at warmer temperatures.
This is why people in the field talk about the order of steps. Cooling for freezing is slow, often less than 1°C per minute. For vitrification, rewarming is pushed as fast as possible. That is not a detail. It is the difference between a process that preserves structure and one that lets damage spread.
Cryonics also includes the practical work around the patient. Standby means being ready when death is near or has just been declared. Stabilization begins at once. That can include cooling, circulation support, and transport to a preservation facility. In recent years, some groups have used sternal infusion as a route for initial neuroprotective delivery. Other work has explored nose delivery for certain neuroprotective agents, though that idea has limits and is not a finished answer.
The science is still narrow in one important sense. About one hundred cryoprotectant compounds have been studied, but only a few are used routinely. One common vitrification solution, called M22, combines penetrating cryoprotectants, an isotonic carrier, and ice blockers. Those blockers, such as X-1000 and Z-1000, are meant to interfere with ice growth rather than enter cells.
None of this proves future revival. It does show that cryonics is built around a real biological problem, not a fantasy of stopping time. The work is about reducing injury step by step, in the hope that future science may one day do something useful with the structure that remains.
For me, that is the honest center of the subject. Cryonics asks whether enough of a person can be kept intact for a later chance to matter. That question is narrower than a promise, and wider than a slogan.
The Longer Horizon keeps that same shape of thought in view: one clear question about cryonics, future preservation, and what hope can honestly mean.
Article by Lea Varga ·